Clinical Trial Update: FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

This clinical trial update notes termination of a Phase 2 study evaluating FOLFIRI plus bevacizumab with or without dalteparin as first-line therapy for advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• FRAGMIN (DALTEPARIN SODIUM)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: University of Southern California | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED